Although PD-L1 status is usually measured through pre-treatment tumor biopsy, the PCD4989g trial demonstrated a significant increase in expression following treatment, suggesting that checkpoint therapy may promote tumor-specific T-cell activation and PD-L1 expression (Emens et al., 2019). This evidence concerns the gene CD274 and neoplasm.